7,642.00

+28.00

+0.37%

52,030.00

+112.00

+0.22%

28,754.75

+220.75

+0.77%

Russell 2000 Futures

2,834.50

+13.20

+0.47%

4.9290

-0.0600

-1.20%

19.42

0.00

0.00%

3,910.40

+11.50

+0.29%

78,039.01

-71.23

-0.09%

Crude Oil Dec 26

100.42

-3.70

-3.55%

US Private Equity

10,850.63

-82.20

-0.75%

Paris - Delayed Quote EUR

Innate Pharma S.A. (IPH.PA)

1.2560 0.0000 (0.00%)

As of October 30 at 5:35:02 PM GMT+1. Market Open.

Loading Chart for IPH.PA

Chart Range Bar

Interval:

In partnership with ChartIQ

Innate Pharma Q4 Earnings Call Highlights

Innate Pharma Q4 Earnings Call Highlights

Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy

Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy

Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...

Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 Target

How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 Target

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround

Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

Mobilize your Website

View Site in Mobile | Classic

Share by: